NASDAQ:INVA Innoviva Q3 2025 Earnings Report $20.66 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$20.66 +0.00 (+0.02%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innoviva EPS ResultsActual EPS$1.08Consensus EPS $0.46Beat/MissBeat by +$0.62One Year Ago EPSN/AInnoviva Revenue ResultsActual Revenue$107.80 millionExpected Revenue$91.31 millionBeat/MissBeat by +$16.50 millionYoY Revenue GrowthN/AInnoviva Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:00PM ETUpcoming EarningsInnoviva's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Innoviva Earnings HeadlinesTheravance Biopharma issues disclosures amid Zymeworks mergerSeptember 10, 2026 | tipranks.comTheravance Biopharma details Phase 3 ampreloxetine dataAugust 25, 2026 | tipranks.comPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon.September 14 at 1:00 AM | Profits Run (Ad)Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product ...August 11, 2026 | uk.finance.yahoo.comInnoviva Inc Share Price (INVA.US)August 7, 2026 | lse.co.ukInnoviva, Inc. (INVA) latest stock news and headlines – Yahoo FinanceAugust 6, 2026 | uk.finance.yahoo.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA) is a biopharmaceutical company focused on developing and commercializing healthcare products through strategic partnerships, royalty arrangements and investments in biotechnology businesses. The company’s portfolio has historically centered on respiratory medicines, with rights connected to products developed with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta. Innoviva generally operates as an asset-focused healthcare company rather than as a traditional commercial pharmaceutical manufacturer. It receives royalties and other economic benefits from partnered products marketed in multiple international markets, while pursuing additional opportunities in biopharmaceutical and healthcare companies. Its portfolio has also included an investment in Armata Pharmaceuticals, which is developing bacteriophage-based therapies intended to treat drug-resistant bacterial infections. The company was previously known as Theravance, Inc. and adopted the Innoviva name in 2016 as its business evolved toward a royalty and strategic-investment model. Innoviva is headquartered in the United States and relies substantially on partners and affiliated companies for the development, regulatory approval and commercialization of its products. Pavel Raifeld serves as the company’s chief executive officer.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
